The effect of therapeutic pleural drainage on the short- and long-term sequelae of tuberculous pleural effusions

E Wilken, MB ChB, FCP; H Fengels, MD; F Swart, ND Clin Tech; D Maree, ND Clin Tech; J W Bruwer, MB ChB, FCP, Cert Pulm; E M Batubara, MD, FCCP, SBIM, SF-AP; E M Irusen, MB ChB, FCP, PhD; C F N Koegelenberg, MB ChB, FCP, FRCPC, PhD

Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

Corresponding author: E Wilken (elismawilken@gmail.com)

Background. Tuberculosis (TB) is the most frequent cause of death due to infectious disease worldwide. Tuberculosis of the pleura, or tuberculous pleuritis, is the second most common extrapulmonary manifestation of TB after TB lymphadenitis. It is well documented in both primary and post-primary TB. Involvement ranges from tuberculous pleurisy to exudative and caseous pleurisy to frank empyema. In the developed world, tuberculous pleural involvement remains rare with TB accounting for <1% of exudates. However, in the developing world, especially in the setting of HIV co-infection, TB may be associated with up to 80% of pleural effusions.

Thoracocentesis is the initial mandatory diagnostic procedure, and typically reveals a lymphocytic exudate, rich in protein, glucose deplete and with elevated lactate dehydrogenase (LDH) and adenosine deaminase (ADA) levels. The diagnostic yield of thoracocentesis is ~93%, which could be improved to 100% with the addition of a thoracoscopic pleural biopsy.

Pleural fibrosis or fibrothorax is a well-described complication of tuberculous pleurisy. Uncertainty remains regarding the prevalence of fibrothorax and permanent pleural thickening, with some sources suggesting a prevalence of 50%, while others suggest that it is as low as 5%. This variation could be explained by differences in demographics and background TB prevalence. Many experienced thoracoscopists believe that complete drainage of the pleural effusion results in a reduction in the development of pleural fibrosis, but empirical data showing a potential benefit of effective drainage of pleural effusion in the prevention of pleural fibrosis are lacking.

In 2003, Lai et al. could not demonstrate a benefit of pleural drainage in the prevention of pleural fibrosis in a randomised trial, but the effectiveness of pleural drainage was not evaluated in that study. In a subsequent study, Chung et al. showed that effective drainage of TB pleural effusion lowered the risk of fibrosis compared with partial drainage. Their data suggested that such drainage might in fact be of benefit in reducing the risk of developing residual pleural fibrosis. Owing to a lack of consensus, the current standard of care for TB pleural effusion does not include pleural drainage and only consists of anti-TB drugs.

Factors that significantly increase the probability of development of pleural fibrosis include the severity of the initial change in pleural glucose, pH and tumour necrosis factor-alpha levels. It has also been suggested that the degree of pleural thickening can be estimated by the response to 2 weeks of anti-TB treatment. Additionally, a septated ultrasonographic appearance of the pleural effusion, a positive TB culture on pleural fluid and an elevated LDH level are also associated with an increased risk of developing pleural fibrosis.

Pulmonary function tests (PFTs) are an objective measure to monitor the response and effectiveness of treatment of TB pleural effusion. The 6-minute walking distance (6MWD) is used to determine objective functional exercise capacity.

Objective

To investigate the additional benefits of once-off pleural drainage in addition to medical management in the prevention of short- and long-term sequelae of tuberculous pleural effusions. The effectiveness of the intervention was measured by looking at changes in PFT results over time.
Methods

Study design and population

This randomised controlled interventional study was carried out from October 2012 to September 2013 in the Division of Pulmonology at Tygerberg Academic Hospital, a 1 200-bed hospital in Cape Town, South Africa (SA). It is one of two referral centres and renders a tertiary service to a population of approximately 1.5 million people. The incidence of pulmonary TB in the Western Cape Province is 933 cases per 100 000 population, the highest recorded incidence after China and India according to the World Health Organization. [14]

Ethical approval for the study was obtained from the Stellenbosch University Human Research Ethics Committee (Ethics ref.: N12/07/040). Every patient gave informed consent to enrol in this study in writing.

Patients aged >18 years with a high clinical suspicion of TB and radiological evidence of a pleural effusion were enrolled. A high clinical suspicion included patients known to have HIV infection and those with a persistent cough lasting >3 weeks, haemoptysis, weight loss of >4 kg, intermittent fever for >3 weeks and drenching night sweats for >2 weeks. Patients were included if they could give written consent and had a chest radiograph (CXR) showing >30% involvement of the hemithorax and at least two clinical indicators to suggest TB. Any patient found not to have TB was excluded from the study. Other exclusion criteria were a recent history of invasive procedures in the pleural cavity or recent penetrating chest wall trauma.

Initial evaluation and management

A baseline CXR with posteroanterior and lateral films along with spirometric assessment according to the guidelines of the American Thoracic Society (ATS) was performed on all patients. [15-18] Initial CXR effusion size was graded as moderate (<50% of a hemithorax), moderate to large (50 - 75% of a hemithorax) or large (>75% of a hemithorax). Spirometrics (MasterScreen Jaeger, Germany, version 02.00, 2011) included a flow-volume loop, diffusion capacity for carbon monoxide (DLco) and plethysmography. To evaluate patients’ functional exercise capacity, we performed a 6MWD according to the ATS criteria [19] and graded symptoms according to Borg. [20] including dyspnoea and exhaustion with a visual analogue scale.

Participants were randomly allocated at a 1:1 ratio to either a control group or an intervention group at the onset of presentation. Diagnostic thoracocentesis (at least 50 ml of pleural fluid) and pleural biopsy (more than four samples) with an Abrams needle were performed in a sitting position and under ultrasound guidance according to standardised guidelines. [21-23] The intervention group received therapeutic once-off pleural fluid drainage with an Arrow percutaneous cavity drainage catheterisation set (Teleflex, SA). Thoracocentesis was suspended if spontaneous cessation of fluid drainage occurred or if the patient experienced discomfort with exacerbation of symptoms or vaginal manifestations. The patient was observed and oxygen therapy given if saturation was <90%.

Follow-up

All participants were followed up after 1 week. The laboratory results were reviewed, anti-TB treatment, where relevant, was continued for at least 6 months and further special investigations, where appropriate, were organised. This was all done according to the standard operating procedure at Tygerberg Academic Hospital. All patients with confirmed pleural TB were subsequently followed up at 3 and 6 months. The CXR (Fig. 1), spirometric assessments and a 6MWD were performed at each visit. The greatest linear width of pleural opacity on the erect PA CXR was classified as follows: <2 mm: radiologically normal; 2 - 4.9 mm: radiologically abnormal; 5 - 10 mm: pleural thickening; and >10 mm: fibrothorax.

Estimated overall pleural thickening was classified as involvement of less than one-third of the hemithorax, one-third to two-thirds of the hemithorax, or more than two-thirds of the hemithorax.

Statistical analysis

The changes in FVC after 1 week and 3 and 6 months were compared with the baseline value. An unpaired t-test at an alpha level of 5% was used to compare the mean change in FVC between the intervention and control groups. Further key secondary endpoints were analysed in line with the primary
endpoints (changes in forced expiratory volume in 1 second (FEV₁), total lung capacity (TLC), DLCO and 6MWD after 1 week and 3 and 6 months). Missing values for assessment of change were replaced with zero, following a conservative strategy. Baseline characteristics were analysed using means and standard deviations (SDs) for continuous and absolute frequencies for categorical variables. A $p$-value of <0.05 was considered significant.

### Outcome

For a short-term sequelae primary outcome parameter we defined change in FVC in litres after 1 week, for medium term after 3 months and for long term after 6 months. Key secondary outcome parameters included changes in FEV₁, TLC, DLCO and 6MWD and the prevalence of fibrothorax after 6 months of treatment. The need for surgery was taken as the main clinical long-term sequelae parameter.

### Results

#### Baseline observations and interventions

Thirty-seven patients were referred for the study, of whom 13 were excluded (3 had empyemas, 3 had pneumonia, 3 had negative results on testing for TB, 1 was <18 years of age and 3 had other reasons). All patients were randomised from the start, and either a diagnostic tap or therapeutic drainage was performed. Eleven patients were randomised to therapeutic pleural drainage, but 1 was lost to follow-up after the initial visit, leaving 10 patients with completed data in each study arm.

The mean age of the 20 patients was 32.7 years (SD 8.7); 12 were HIV-positive. The general characteristics of the group are summarised in Table 1 and the results of diagnostic thoracocentesis in Table 2. The mean volume drained during therapeutic drainage was 1 139 mL (SD 711, range 250 - 2 700). Aspiration was abandoned in 6 patients owing to suspected re-expansion pulmonary oedema and/or discomfort.

#### Primary and key secondary outcomes

Lung function parameters measured at baseline, 1 week, 3 months and 6 months are summarised in Tables 3 - 5.

With regard to the primary outcome variable, patients randomised to therapeutic drainage experienced a significantly greater improvement in FVC than the control group at 3 months (mean difference 1.40 L (SD 0.44) in the intervention group v. 0.34 L (SD 0.46) in the control group; $p$<0.001) and at 6 months (1.40 L (SD 0.44) v. 0.65 L (SD 0.39); $p$<0.001) (Fig. 2A). The mean percentage predicted change in FVC from baseline in the intervention group was significantly higher than in the control group at 3 months (mean difference 1.37 L (SD 0.56) v. 0.60 L (SD 0.34); $p$=0.002) and at 6 months (1.37 L (SD 0.56) v. 0.65 L (SD 0.39); $p$=0.001) (Fig. 2A).

FEV₁ in the intervention group improved significantly, with a mean change from baseline at 3 months of 1.08 L (SD 0.41) v. 0.38 L (SD 0.42); $p$=0.001 in the control group and 1.37 L (SD 0.56) v. 0.60 L (SD 0.34); $p$=0.002 at 6 months (Fig. 2B).

Patients randomised to therapeutic drainage also experienced significantly greater improvement in TLC, with a change of 1.45 L (SD 0.56) v. 0.56 L (SD 0.78); $p$=0.009 at 3 months, and 1.76 L (SD 0.94) v. 0.88 L (SD 0.76); $p$=0.034 at 6 months (Fig. 2C).

Changes in DLCO after 3 months (mean change 6.43 mL/min/mmHg (SD 3.77) in the intervention group v. 0.57 mL/min/mmHg (SD 4.18) in the control group; $p$=0.005) and 6 months (7.42 mL/min/mmHg (SD 4.63) in the intervention group v. 2.19 mL/min/mmHg (SD 3.84) in the control group; $p$=0.013) were also statistically significant (Fig. 2D).

6MWD improved in both groups, being 113.5 m (SD 64.6) in the intervention group v. 85.9 m (SD 69.4) in the control group ($p$=0.369) at 3 months and 113.4 m (SD 131.02) in the intervention group v. 126 m (SD 78.8) in the control group ($p$=0.798) at 6 months. Improvement in the intervention group was not significantly superior to that in the control group (Fig. 2E).

As no patient showed severe restriction (FVC <50%) after 3 or 6 months, surgery was not considered in any patient.

#### Complications

Initial pleural aspiration and biopsy were uncomplicated in all study patients. Re-expansion pulmonary oedema and/or patient discomfort resulted in the premature termination of 6 of the 10 attempts at complete pleural drainage. The procedure was stopped as soon as the patient experienced symptoms of distress or discomfort, and the patient was observed and given supplemental oxygen if the saturation was <$90%. Patients recovered quickly, and no patient needed admission. The procedure was also abandoned if the drainage of fluid

#### Table 1. Clinical and radiological characteristics of the study population (N=20)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Study group (n=10)</th>
<th>Control group (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>27.9 (6.8)</td>
<td>37.5 (10.63)</td>
</tr>
<tr>
<td>Weight (kg), mean (SD)</td>
<td>61.6 (14.1)</td>
<td>56.7 (10.14)</td>
</tr>
<tr>
<td>Height (cm), mean (SD)</td>
<td>164.0 (7.0)</td>
<td>164.45 (11.8)</td>
</tr>
<tr>
<td>Males/females, n</td>
<td>3/7</td>
<td>7/3</td>
</tr>
<tr>
<td>HIV-positive, n</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Loculations, n</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

#### Table 2. Pleural fluid and blood results in the study population (N=20)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Study group (n=10)</th>
<th>Control group (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADA (U/L)</td>
<td>72.56</td>
<td>749.1</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>63.6</td>
<td>4.1</td>
</tr>
<tr>
<td>Total protein (g/L)</td>
<td>81.55</td>
<td>13.0</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>4.1</td>
<td>5.1</td>
</tr>
<tr>
<td>pH</td>
<td>7.3</td>
<td>7.3</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>293.11</td>
<td>80.8</td>
</tr>
<tr>
<td>Blood</td>
<td>13.0</td>
<td>5.1</td>
</tr>
</tbody>
</table>

SARJ VOL. 22 NO. 3 2016 63
spontaneously ceased. No pneumothorax or major haemorrhage resulted.

**Discussion**

We found that at 3 and 6 months’ follow-up, patients with confirmed tuberculous pleural effusions randomised to therapeutic pleural drainage showed significantly superior improvement in several lung function parameters to those who did not receive drainage. This included changes in FVC, FEV₁, TLC and DLCO, despite the fact that complete drainage as per protocol was achieved in less than half of all patients randomised to undergo the intervention. Draining off as much fluid as possible seemed to be more beneficial than anti-TB treatment alone.

In 1996, Wyser et al.[25] investigated the influence of corticosteroids on TB pleural effusions and concluded that standard anti-TB therapy and early complete drainage are adequate for the treatment of TB pleurisy. Their study did not include a control group. A subsequent randomised controlled trial by Lai et al.[9] found that the addition of pleural drainage to anti-TB medical treatment did not have a beneficial effect on restrictive pulmonary thickness (RPT) development or shorten the duration of fever or other clinical symptoms. Lai et al.[9] failed to show a significant improvement in FVC (treatment group 85.5% v. control group 88%; \(p=0.568\)), TLC and FEV₁ were not measured, and effectiveness of drainage was not evaluated. Dyspnoea was the only proven benefit, and showed faster improvement in the drained group (median 4 days v. 8 days; \(p<0.001\)).

In contrast, a recent study by Bhuniya et al.[26] showed significant differences in mean percentage predicted FEV₁ (drained group 87.62% v. control group 84.92%; \(p=0.02\)) and FVC (84.46 L v. 83.31 L; \(p=0.001\)) after 6 months, drainage being performed using pleural manometry. They reported a lower appearance of RPT in patients who underwent drainage and commented that patients with therapeutic thoracocentesis experienced immediate relief from dyspnoea after drainage, although this finding was not substantiated with any objective measure.

Previous studies have reported immediate improvement in FVC and FEV₁, with both showing an increase in excess of 10% after thoracocentesis of large pleural effusions.[27-29] We did not find any immediate improvement in FVC or FEV₁ after the procedure, but this may be due to pain and coughing caused by the drainage process. TLC showed a significant immediate improvement (3.00 L before drainage v. 3.40 L after drainage; \(p=0.047\)).
We used the 6MWD to objectively evaluate performance-based functional exercise capacity. It is a cheap and easy test to perform,[19] but unfortunately only measures the submaximal level of functional capacity, and the results are influenced by the patient's own motivation and set pace. We did not find any difference in 6MWD (as measured by Borg[20]) between the two groups at any time during follow-up. The minimal clinical important difference for the 6MWD is estimated to be between 54 m and 80 m,[30] which both groups achieved at 3 and 6 months. The lack of statistical significance could be explained by the study being under-powered for the effect, or may suggest that a different objective test should have been used.[19]

Another consideration is that both groups’ performance-based functional exercise capacity improved despite intervention.

On the other hand, most patients experienced clinical improvement of chest pain and relief of dyspnoea after drainage of the effusion. The greatest dyspnoea relief was achieved immediately after drainage, which confirms findings of former studies.[25,26,31]

Although our numbers were small, it appears that complete drainage seems to reduce RPT. Earlier studies reported that an RPT of >10 mm caused significant clinical symptoms in patients with pleural TB, with incidences ranging from 26% to 50.4%.[9,26,32] In our study there were twice as many patients with an RPT of >10 mm (60%) in the control group than in the intervention group (30%), which is in accordance with similar current studies.[32]

In contrast to previous studies,[16,25] ours was a randomised controlled trial and as such we focused on FVC improvement and investigated the influence of drainage on all lung function parameters, including TLC and DLco. Another difference to previous studies[6,30] is that we decided to use a single once-off drainage for achieving dryness of pleural effusion, not pigtail drainage over several days. The value of this is that once-off drainage is an available treatment procedure, simple to perform at primary healthcare level. Moreover, we evaluated effectiveness of drainage after the procedure.

**Study limitations**

A limitation of our study is that despite randomisation, the two groups differed with regard to their baseline characteristics. From the outset, the intervention group had larger effusion sizes, higher dyspnoea grades and more restriction in lung function parameters. Nevertheless, the intervention group achieved significant improvement in primary and key secondary outcomes. Further limitations are the small number of patients and the inability to obtain complete dryness of effusion continuously, as defined in the protocol. Dyspnoea associated with pulmonary re-expansion is well known to limit the maximum volume drained.[31-36]

**Conclusion**

Therapeutic drainage may offer additional medium- and long-term functional benefits to patients with large tuberculous pleural effusions, as is evident by the statistically significant improvement in PFT results compared with anti-TB drugs alone. Pleurodesis is generally a safe procedure, and easy to perform in the primary care setting. We recommend draining the maximum amount of fluid the patient finds comfortable, or continuing until drainage stops spontaneously. This should be followed up by chest radiography to exclude any complications.

**Acknowledgement.** Funding was obtained from the Susan de Kock bursary for postgraduate study in 2013.

---

**Table 5. Lung function parameters (mean (SD)) of all study patients after 3 and 6 months**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Variable</th>
<th>Follow-up, 3 months</th>
<th>Follow-up, 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Not drained (n=10)</strong></td>
<td>Therapeutic drainage (n=10)</td>
<td><strong>Not drained (n=10)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>p-value</strong></td>
<td><strong>p-value</strong></td>
<td><strong>p-value</strong></td>
</tr>
<tr>
<td>FVC</td>
<td>Absolute (L)</td>
<td>2.46 (0.59)</td>
<td>3.06 (0.72)</td>
</tr>
<tr>
<td></td>
<td>% predicted</td>
<td>64.7 (9.6)</td>
<td>79.3 (11.2)</td>
</tr>
<tr>
<td>Change from baseline (L)</td>
<td>0.34 (0.46)</td>
<td>1.40 (0.44)</td>
<td>0.001</td>
</tr>
<tr>
<td>% change</td>
<td>9.0 (12.7)</td>
<td>36.3 (9.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV₁</td>
<td>Absolute (L)</td>
<td>2.12 (0.62)</td>
<td>2.53 (0.61)</td>
</tr>
<tr>
<td></td>
<td>% predicted</td>
<td>67.5 (14.7)</td>
<td>76.4 (12.6)</td>
</tr>
<tr>
<td>Change from baseline (L)</td>
<td>0.38 (0.42)</td>
<td>1.08 (0.41)</td>
<td>0.001</td>
</tr>
<tr>
<td>% change</td>
<td>13.7 (14.3)</td>
<td>32.5 (11.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>TLC</td>
<td>Absolute (L)</td>
<td>4.57 (0.94)</td>
<td>4.45 (0.80)</td>
</tr>
<tr>
<td></td>
<td>% predicted</td>
<td>81.5 (15.9)</td>
<td>84.1 (9.5)</td>
</tr>
<tr>
<td>Change from baseline (L)</td>
<td>0.56 (0.78)</td>
<td>1.45 (0.56)</td>
<td>0.009</td>
</tr>
<tr>
<td>% change</td>
<td>8.2 (14.8)</td>
<td>27.5 (8.1)</td>
<td>0.002</td>
</tr>
<tr>
<td>DLco</td>
<td>Absolute (mL/min/mmHg)</td>
<td>16.17 (4.52)</td>
<td>20.75 (3.78)</td>
</tr>
<tr>
<td></td>
<td>% predicted</td>
<td>58.0 (10.8)</td>
<td>72.2 (6.8)</td>
</tr>
<tr>
<td>Change from baseline (mL/min/mmHg)</td>
<td>0.57 (4.18)</td>
<td>6.43 (3.77)</td>
<td>0.005</td>
</tr>
<tr>
<td>% change</td>
<td>2.0 (14.0)</td>
<td>22.1 (12.1)</td>
<td>0.004</td>
</tr>
<tr>
<td>6MWD</td>
<td>Absolute (m)</td>
<td>551.3 (93.8)</td>
<td>566.1 (81.1)</td>
</tr>
<tr>
<td>Change from baseline (m)</td>
<td>85.9 (69.4)</td>
<td>113.5 (64.6)</td>
<td>0.369</td>
</tr>
</tbody>
</table>
References


Fig. 2. Mean changes in absolute (A) FVC, (B) FEV₁, (C) TLC, (D) DLCO, and (E) 6MWD from baseline.